MediGene AG's partner in the United States, Atrix Laboratories Inc., of Fort Collins, Colo., received market approval from the FDA for an additional dose of Eligard, its compound for the treatment of advanced prostate cancer. MediGene, of Martinsried, Germany, owns the exclusive European rights to the compound, which has been submitted to German authorities for market approval.

No Comments